 |
|
Pharmacotherapy for Asthma and Chronic Obstructive Pulmonary DiseaseCurrent Thinking, Practices, and Controversies
Morton S. Skorodin, MD
Arch Intern Med. 1993;153(7):814-828.
Abstract
A number of new medications for treatment of asthma and chronic obstructive pulmonary disease have been developed in recent years. However, serious issues persist in the management of these illnesses. Prevalence, morbidity, and mortality of asthma are increasing despite the introduction of these new agents. Airflow obstruction is only partially reversible in chronic obstructive pulmonary disease, and drug treatment can only mitigate disability incompletely. Drug toxicity is also an important concern. The five classes of agents (β-adrenergic agonists, anticholinergic agents, theophylline, cromolyn, and corticosteroids) available for treatment are examined in this review, emphasizing efficacy and toxicity. Less commonly used agents and newly developed compounds that are still investigational are also discussed.
Author Affiliations
From the Ambulatory Care Service and Division of Pulmonary and Critical Care Medicine, Edward Hines Jr Veterans Affairs Hospital, Hines, and Department of Medicine, Stritch School of Medicine, Loyola University of Chicago, Maywood, Ill.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Inhaled Steroids and the Risk of Hospitalization for Asthma
Donahue et al.
JAMA 1997;277:887-891.
ABSTRACT
Lack of Effectiveness of Magnesium in Chronic Stable Asthma: A Prospective, Randomized, Double-blind, Placebo-Controlled, Crossover Trial in Normal Subjects and in Patients With Chronic Stable Asthma
Bernstein et al.
Arch Intern Med 1995;155:271-276.
ABSTRACT
Can the Nebulizer Survive?
Tenholder and Whitlock
Arch Intern Med 1993;153:2389-2389.
ABSTRACT
|
